Kidney Infection Market Research Report - Forecast till 2027

Kidney Infection Market Research Report: By Diagnosis (Dipstick Urine Test, Imaging Test, Treatment (Medication, Antibiotics, Nsaids, Dialysis, Kidney Transplant), End User (Hospitals & Clinics, Nephrology Center, Research Institutes) - Forecast till 2027

ID: MRFR/LS/3754-HCR | | Region: Global | 110 pages

Kidney Infection Market Scenario


Kidney infection is a result of infection in the bladder that spreads to the kidney. Most common bacteria causing kidney infection is E. coli. Kidney infections are very common, especially, an aging population. The blood test is performed to make sure that the kidneys are functioning normally. The urine test, called a urinalysis, detects any abnormal cells or proteins that relate to a kidney problem. If the blood and urine tests are normal, then no other tests are required. In some cases, these infections are diagnosed when a person undergoes an ultrasound examination or CT scan of the abdomen for some other reason. Additionally, the urologist may suggest an X-ray examination called “Voiding Cystourethrogram”.


Increasing prevalence of kidney infections, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the kidney infection market. Furthermore, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases are likely to fuel the kidney infection market growth during the forecast period. Moreover, increasing geriatric population is projected to boost the kidney infection market growth. Established market players in the developed countries lead the globalization by pushing new products and services into the developing countries and emerging economies. However, higher treatment cost may hinder the kidney infection market growth over the review period.


As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Kidney disease is often referred to as a “silent disease” as there are no symptoms in its early stages and can go undetected. Chronic kidney disease (CKD) is a global health burden risk factor for cardiovascular disease (CVD). High blood pressure and diabetes are the main causes of CKD. The high economic cost to health systems and decreased productivity are the major drawbacks of kidney diseases. NIDDK also stated that the overall prevalence of Chronic Kidney Disease (CKD) in the general population is approximately 14%. It also stated that in 2013, Medicare spending for patients with CKD aged 65 and older exceeded USD 50 billion, which accounted for 20% of total Medicare spending in this age group. Over 70% of the Medicare spending for CKD patients aged 65 and older was incurred by those who also had diabetes, congestive heart failure, or both.


The kidney infection market is expected to grow at a CAGR of ~5.2% during the forecast period 2017-2023.


Research Methodology
Kidney Infection Market


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Pharmaceutical and Biotechnological Companies

  • Research and Development (R&D) Companies

  • Ambulatory Care Centers

  • Academic Institutes and Universities

  • Market Research and Consulting Service Providers

  • Potential Investors


Segmentations


The kidney infection market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of the diagnosis, kidney infection market is segmented into dipstick urine test and imaging test. The imaging test is further segmented into ultrasound, CT scan, voiding cystourethrogram, and others.


The treatment segment is divided into medication, dialysis, kidney transplant, and others. The medication is further segmented into antibiotics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Based on the end user, kidney infection market is segmented into hospitals & clinics, nephrology center, research institutes, and others.


Regional Analysis


The Americas dominate the kidney infection market owing to the availability of technologically advanced medical devices for diagnosis and treatment of kidney infection such as dialysis machine, increasing patient population for a kidney infection, increasing government support for research & development, and high health care spending. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the kidney infection market in this region.   


The European region is exhibiting flourishing growth owing to the increasing emphasis on the development of new drugs, rising government support for research & development, and availability of funds for research. Rising number of specialty services offered by various healthcare providers in Europe also accelerate the growth of the kidney infection market. For instance, developed economies such as Germany and France are increasing investment in the healthcare domain and are focusing more on the hospital infrastructure.      


The Asia Pacific is the fastest growing kidney infection market owing to the presence of rapidly developing healthcare technology and high healthcare expenditure. Moreover, increasing patient population in countries such as India is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may speed up the market growth in this region.    


However, the Middle East & Africa holds the least share of the kidney infection market due to less availability of funds, limited medical facilities, and unavailability technologically advanced medical devices.


Figure: Kidney Infection Market, By Region Market Share, 2016 (%)


Kidney Infection Market
Sources: Annual reports, Press release, White paper, Company presentation

Key Players


AbbVie, Inc. (U.S.), Allergan plc. (U.K), Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (U.K), Johnson & Johnson Services Inc. (U.S.), Keryx Biopharmaceuticals, Inc. (U.S.), Kissei Pharmaceutical Co. Ltd. (Japan), Pfizer (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Japan), and others.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   5.2% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AbbVie, Inc. (U.S.), Allergan plc. (U.K), Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (U.K), Johnson & Johnson Services Inc. (U.S.), Keryx Biopharmaceuticals, Inc. (U.S.), Kissei Pharmaceutical Co. Ltd. (Japan), Pfizer (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Japan), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of kidney infections
  • Increasing investment by biotechnology and pharmaceutical industries in R&D
  • Rising need for the better treatment methods


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The kidney infection market CAGR would be 5.2% CAGR during the forecast period.

    The end users mentioned in the report are hospitals & clinics, nephrology centers, research centers, and others.

    The Americas would dominate the global kidney infection market.

    The Asia Pacific kidney infection market would lead the global market in terms of CAGR.

    High treatment cost and diving productivity can hamper the kidney infection market prospect.

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Kidney Infection Market, by Diagnosis

    6.1 Introduction

    6.2 Dipstick Urine Test

    6.2.1 Market Estimates & Forecast, 2020-2027

    6.3 Imaging Test

    6.3.1 Market Estimates & Forecast, 2020-2027

    6.4 Others

    6.4.1 Market Estimates & Forecast, 2020-2027

    7. Global Kidney Infection Market, by Treatment

    7.1 Introduction

    7.2 Medication

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.3 Dialysis

    7.3.1 Market Estimates & Forecast, 2020-2027

    7.4 Kidney Transplant

    7.4.1 Market Estimates & Forecast, 2020-2027

    7.5 Others

    7.5.1 Market Estimates & Forecast, 2020-2027

    8. Global Kidney Infection Market, by End User

    8.1 Introduction

    8.2 Hospital & Clinics

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 Nephrology Centers

    8.3.1 Market Estimates & Forecast, 2020-2027

    8.4 Research Institutes

    8.4.1 Market Estimates & Forecast, 2020-2027

    8.4 Others

    8.4.1 Market Estimates & Forecast, 2020-2027

    9. Global Kidney Infection Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 U.S.

    9.2.1.1 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 U.K.

    9.3.1.4 Italy

    9.3.1.5 Spain

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    10 Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    11 Company Profiles

    11.1 AbbVie, Inc.

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.2 Allergan plc.

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.3 Amgen Inc.

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.4 AstraZeneca

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.5 F. Hoffmann-La Roche Ltd

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 GlaxoSmithKline plc.

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.7 Johnson & Johnson Services Inc.

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.8 Others

    12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Kidney Infection Industry

    13 Appendix

    LIST OF TABLES

    Table 1 Kidney Infection Industry Synopsis, 2020-2027

    Table 2 Global Kidney Infection Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global Kidney Infection Market by Region, 2020-2027, (USD Million)

    Table 4 Global Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 5 Global Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 6 Global Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 7 North America Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 8 North America Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 9 North America Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 10 U.S. Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 11 US Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 12 US Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 13 Canada Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 14 Canada Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 15 Canada Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 16 South America Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 17 South America Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 18 South America Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 19 Europe Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 20 Europe Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 21 Europe Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 22 Western Europe Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 23 Western Europe Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 24 Western Europe Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 25 Eastern Europe Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 26 Eastern Europe Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 27 Eastern Europe Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 28 Asia Pacific Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 29 Asia Pacific Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 30 Asia Pacific Kidney Infection Market by End Users, 2020-2027, (USD Million)

    Table 31 Middle East & Africa Kidney Infection Market by Diagnosis, 2020-2027, (USD Million)

    Table 32 Middle East & Africa Kidney Infection Market by Treatment, 2020-2027, (USD Million)

    Table 33 Middle East & Africa Kidney Infection Market by End Users, 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Kidney Infection Market

    Figure 3 Segmentation Market Dynamics for Kidney Infection Market

    Figure 4 Global Kidney Infection Market Share, by Diagnosis 2020

    Figure 5 Global Kidney Infection Market Share, by Treatment 2020

    Figure 6 Global Kidney Infection Market Share, by End Users, 2020

    Figure 7 Global Kidney Infection Market Share, by Region, 2020

    Figure 8 North America Kidney Infection Market Share, by Country, 2020

    Figure 9 Europe Kidney Infection Market Share, by Country, 2020

    Figure 10 Asia Pacific Kidney Infection Market Share, by Country, 2020

    Figure 11 Middle East & Africa Kidney Infection Market Share, by Country, 2020

    Figure 12 Global Kidney Infection Market: Company Share Analysis, 2020 (%)

    Figure 13 Boston Scientific Corp: Key Financials

    Figure 14 Boston Scientific Corp: Segmental Revenue

    Figure 16 Boston Scientific Corp: Geographical Revenue

    Figure 17 C.R. Bard Inc. Key Financials

    Figure 18 C.R. Bard Inc. Segmental Revenue

    Figure 19 C.R. Bard Inc. Geographical Revenue

    Figure 20 Convergent Laser Technologies. Key Financials

    Figure 21 Convergent Laser Technologies. Segmental Revenue

    Figure 22 Convergent Laser Technologies: Geographical Revenue

    Figure 23 Cook Medical Inc: Key Financials

    Figure 24 Cook Medical Inc: Segmental Revenue

    Figure 25 Cook Medical Inc: Geographical Revenue

    Figure 26 DirexGroup: Key Financials

    Figure 27 DirexGroup: Segmental Revenue

    Figure 28 DirexGroup: Geographical Revenue

    Figure 29 Dornier MedTech GmbH: Key Financials

    Figure 30 Dornier MedTech GmbH: Segmental Revenue

    Figure 31 Dornier MedTech GmbH: Geographical Revenue